Votrient (Pazopanib) 200mg/400mg*30 | Novartis India | GLT

Generic Information: Votrient (Pazopanib) 200mg/400mg — India

This is the India presentation of Votrient, the originator pazopanib marketed by Novartis. Pazopanib was developed by GlaxoSmithKline and later transferred to Novartis. This listing is manufactured by Novartis India Limited and offers two tablet strengths — 200 mg and 400 mg — each in 30-tablet packs. The 400 mg tablet allows patients to take the standard 800 mg once-daily dose as just two tablets instead of four.

India is a major hub for pharmaceutical manufacturing, and the Novartis India presentation of Votrient reflects the originator's regional supply. Buyers should confirm which strength they require, as the 200 mg and 400 mg presentations serve the same dosing regimen but differ in tablet count and convenience.

What Is Votrient Used For?

Votrient is indicated for advanced renal cell carcinoma (RCC) in the first-line setting and after prior cytokine therapy, and for advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. Pazopanib's anti-angiogenic effect is the basis of its activity in both of these vascular-driven cancers.

How Does Votrient Work?

Pazopanib is a multi-targeted tyrosine kinase inhibitor that primarily blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β) and c-Kit. By inhibiting these kinases, Votrient disrupts tumour angiogenesis, cutting off the new blood supply that growing tumours require and slowing their progression.

Indications

• Advanced renal cell carcinoma (RCC), first-line and after prior cytokine therapy.
• Advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

Dosage and Administration

The recommended dose is 800 mg once daily, taken on an empty stomach (at least 1 hour before or 2 hours after a meal). This is achieved with four 200 mg tablets or two 400 mg tablets. Tablets are swallowed whole and not crushed. A 30-tablet pack provides about one week of therapy. Dose adjustment is needed for hepatic impairment, and liver function and blood pressure are monitored.

Side Effects

Common adverse reactions include diarrhoea, hypertension, hair colour changes, nausea, fatigue, decreased appetite and vomiting. Votrient carries a boxed warning for severe hepatotoxicity, so liver function is monitored before and during treatment. Hypothyroidism, haemorrhage and QT prolongation may occur, and patients should report yellowing, unusual bleeding or palpitations.

Storage

Store below 30°C in the original package, away from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the GLT?

GLT can source the originator Votrient and its regional presentations for buyers who specifically require the Novartis brand, with documentation for import and compliance. The US list price of pazopanib is high — several thousand dollars per month — so GLT helps institutions and patients identify the most cost-effective compliant supply route, including the India presentation where appropriate.

How to Order Votrient (India) from GLT

Contact GLT on WhatsApp at +86 15234153837 or email [email protected] to inquire about Votrient 200 mg or 400 mg (30 tablets). Specify your required strength, quantity and destination, and we confirm pricing, batch origin and export documentation before dispatch.

FAQ

What strengths of Votrient are available in India? This listing offers 200 mg and 400 mg tablets, both in 30-tablet packs.

How many tablets per day? The 800 mg daily dose is four 200 mg tablets or two 400 mg tablets, taken on an empty stomach.

Is Votrient the original pazopanib? Yes, Votrient is the originator brand now marketed by Novartis.